Cargando…

Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy

Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Tomoyasu, Arai, Yasuyuki, Kitawaki, Toshio, Nishikori, Momoko, Mizumoto, Chisaki, Kanda, Junya, Yamashita, Kouhei, Nagao, Miki, Takaori-Kondo, Akifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495341/
https://www.ncbi.nlm.nih.gov/pubmed/37696885
http://dx.doi.org/10.1038/s41598-023-42159-1
_version_ 1785104872531558400
author Jo, Tomoyasu
Arai, Yasuyuki
Kitawaki, Toshio
Nishikori, Momoko
Mizumoto, Chisaki
Kanda, Junya
Yamashita, Kouhei
Nagao, Miki
Takaori-Kondo, Akifumi
author_facet Jo, Tomoyasu
Arai, Yasuyuki
Kitawaki, Toshio
Nishikori, Momoko
Mizumoto, Chisaki
Kanda, Junya
Yamashita, Kouhei
Nagao, Miki
Takaori-Kondo, Akifumi
author_sort Jo, Tomoyasu
collection PubMed
description Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6–15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter.
format Online
Article
Text
id pubmed-10495341
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104953412023-09-13 Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy Jo, Tomoyasu Arai, Yasuyuki Kitawaki, Toshio Nishikori, Momoko Mizumoto, Chisaki Kanda, Junya Yamashita, Kouhei Nagao, Miki Takaori-Kondo, Akifumi Sci Rep Article Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6–15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter. Nature Publishing Group UK 2023-09-11 /pmc/articles/PMC10495341/ /pubmed/37696885 http://dx.doi.org/10.1038/s41598-023-42159-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jo, Tomoyasu
Arai, Yasuyuki
Kitawaki, Toshio
Nishikori, Momoko
Mizumoto, Chisaki
Kanda, Junya
Yamashita, Kouhei
Nagao, Miki
Takaori-Kondo, Akifumi
Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
title Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
title_full Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
title_fullStr Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
title_full_unstemmed Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
title_short Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
title_sort risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495341/
https://www.ncbi.nlm.nih.gov/pubmed/37696885
http://dx.doi.org/10.1038/s41598-023-42159-1
work_keys_str_mv AT jotomoyasu riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT araiyasuyuki riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT kitawakitoshio riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT nishikorimomoko riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT mizumotochisaki riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT kandajunya riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT yamashitakouhei riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT nagaomiki riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy
AT takaorikondoakifumi riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy